Search

Nilabh Te Shastri

from Richmond, CA
Age ~72
Get Report
Also known as:
Nilabh I
Phone and address:
6219 Plymouth Ave, Richmond, CA 94805
(510) 236-2349
Related to:
Avantika Shastri, 46Amita Shastri, 68
Connected to:
Ajay G Shastri, 55Ananda Shastri, 58Anup P Shastri, 57Ashok Shastri, 51Girish R Shastri, 56Jay M Shastri, 61Karan P Shastri, 37Murli R Shastri, 58Neil Shastri, 32Nipa L Shastri, 54

Nilabh Shastri Phones & Addresses

  • 6219 Plymouth Ave, Richmond, CA 94805 (510) 236-2349 (510) 231-9199
  • El Cerrito, CA
  • Cambridge, MA
  • Palo Alto, CA
  • 1500 Arlington Blvd, Arlington, VA 22209
  • 6219 Plymouth Ave, Richmond, CA 94805

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Publications

Us Patents

Eraap Modulators Regulate Immune Responses

View page
US Patent:
7232570, Jun 19, 2007
Filed:
Dec 13, 2005
Appl. No.:
11/300169
Inventors:
Nilabh Shastri - Richmond CA, US
Thomas Serwold - El Cerrito CA, US
Assignee:
Regents of the University of California - Oakland CA
International Classification:
A61K 38/08
A61K 38/04
US Classification:
4241851, 530330
Abstract:
An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.

Diagnosis Of Prostate Cancer With Spas-1 Cancer Antigen

View page
US Patent:
7704701, Apr 27, 2010
Filed:
Jan 29, 2007
Appl. No.:
11/699879
Inventors:
James P. Allison - Berkeley CA, US
Marcella Fasso - Oakland CA, US
Nilabh Shastri - Richmond CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/574
US Classification:
435 723, 435 721
Abstract:
Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer, or can be used for the diagnosis of cancer and the monitoring of cancer progression.

Spas-1 Cancer Antigen

View page
US Patent:
20020150588, Oct 17, 2002
Filed:
Sep 13, 2001
Appl. No.:
09/952432
Inventors:
James Allison - Berkeley CA, US
Marcella Fasso - Oakland CA, US
Nilabh Shastri - Richmond CA, US
International Classification:
A61K039/00
C07H021/04
C12P021/02
C12N005/06
C07K014/435
US Classification:
424/185100, 530/350000, 435/069100, 435/325000, 435/320100, 536/023200
Abstract:
Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer, or can be used for the diagnosis of cancer and the monitoring of cancer progression

Eraap Modulators Regulate Immune Responses

View page
US Patent:
20030228314, Dec 11, 2003
Filed:
Jun 6, 2002
Appl. No.:
10/164012
Inventors:
Nilabh Shastri - Richmond CA, US
Thomas Serwold - El Cerrito CA, US
Assignee:
The Regents of the University of California
International Classification:
A61K039/395
A61K048/00
US Classification:
424/146100, 514/044000
Abstract:
An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
Control profile
Nilabh Te Shastri from Richmond, CA, age ~72 Get Report